Top Markets
Coin of the day
BioVaxys Technology Corp. BioVaxys Technology Corp.

BioVaxys Technology Corp.

BIOV
Hisse Senetlerindeki Sıralama #37710
BioVaxys Technology Corp. is a clinical-stage biotechnology company... BioVaxys Technology Corp. is a clinical-stage biotechnology company specializing in the development of vaccine platforms designed to combat both viral infections and cancer. The company's pipeline includes BVX-0320, a single-strain vaccine for SARS-CoV-2, and BVX-0918A, an experimental haptenized tumor cell vaccine targeting ovarian cancer. Additionally, BioVaxys offers CoviDTH, an immunodiagnostic tool to detect immune system activity in SARS-CoV-2-exposed patients. Further initiatives encompass Papilocare, aimed at HPV-dependent cervical lesions, along with BVX-0918C for cervical cancer, the HPV viral vaccine BVX-0204, and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys has established strategic collaborations, such as a bioproduction agreement with WuXi Biologics Limited to manufacture SARS-CoV-2 s-proteins crucial for BVX-0320 and CoviDTH. It also holds a research partnership with The Ohio State University, Wexner School of Medicine, focusing on BVX-0320, and has engaged Bioanalytical Systems, Inc. for preclinical toxicology evaluations of its CoviDTH immunodiagnostic. The company is headquartered in Vancouver, Canada.
Hisse Fiyatı
$0.05137558
Son senkronizasyon: 2026-06-01
Piyasa Değeri
$1.50M
Değişim (1 gün)
0.00%
Değişim (1 yıl)
-71.60%
Ülke
CA
Ticaret BioVaxys Technology Corp. (BIOV)

Kategori

BioVaxys Technology Corp. (BIOV) için temettü verimi geçmişi
BioVaxys Technology Corp. (hisse sembolü: BIOV) temettü verimi (TTM) 2026 itibariyle: 0
Son 5 yılın ortalama temettü verimi: 0.00%
BioVaxys Technology Corp. (BIOV) için 2026 - 2026 arası temettü verimi geçmişi
Her yılın sonunda temettü verimi (TTM)
Yıl Temettü Verimi Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakiplerin temettü verimi (TTM)